• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Avelos Therapeutics

Monday, June 03, 2024
CP
Oncology
- Avelos is a cutting-edge science based oncology drug development company, particularly focusing on small molecule drugs for novel targets in the areas of synthetic lethality, DNA damage repair and cell cycle. - The company was founded in Sep. 2021, and is headquartered in Seoul. - The founding members include Young-Whan Park (ex-Merck), Soongyu Choi (ex-Bayer), Kangsik Yun (ex-National Oncoventure), who have strong expertise and networks in new drug discovery and development. - Currently, Avelos has 4 oncology drug programs. AVS1001, the first-in-class DNA damage repair & cell cycle inhibitor program, is in IND enabling stage, the others are in lead optimization stage. - The company closed a $8 million Series A financing in 2022, and Series B financing is ongoing.
Avelos Therapeutics
Company Website: http://www.avelostx.com
Lead Product in Development: - AVS1001 : Oncology, NCE, Cell cycle and DNA Damage Response target (preclinical) - AVS1002 : Oncology, NCE, DNA Damage Response target (Discovery) - AVS1003 : Oncology, NCE, DNA Damage Response target (Discovery) - AVS1004 : Oncology, NCE, DNA Damage Response target (Discovery)
Number Of Unlicensed Products (For Which You Are Seeking Partners): 4 oncology drug products

Company HQ City

Seoul

Company HQ State

Seoul

Company HQ Country

Korea, Republic of

CEO/Top Company Official

- CEO : Dr. Young-Whan Park - CTO : Dr. Soongyu Choi - Head of BD : Mr. Kangsik Yun

Development Phase of Primary Product

Pre-Clinical
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS